Side-by-side · Research reference

MazdutidevsOvagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED19/62 cited

BTheoreticalHUMAN-REVIEWED2/42 cited

Mazdutide

GLP-1/Glucagon Dual Agonist · Oxyntomodulin Analogue · Phase 3

9 mgWeekly doseJi 2026

12.4%Weight lossAzam 2026

Phase 3Status (China)

SQ · Abdomen · Once WeeklyJi 2026

Ovagen

Khavinson Bioregulator · Ovarian

OvarianTarget tissue

Di/Tri-peptidePeptide length

AnimalEvidence tier

Oral / SQ · Protocol varies

01Mechanism of Action

Parameter

Mazdutide

Ovagen

Primary target

GLP-1 receptor and glucagon receptorAbdul 2026 Elmendorf 2026

Ovarian tissue chromatin complexes

Pathway

Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026 Abulehia 2026

Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation

Downstream effect

Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D

Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration

Feedback intact?

Yes — physiological receptor-mediated signaling preserved

Presumed physiological — Khavinson peptides described as regulatory, not replacement

Origin

Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity

Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)

Antibody development

—

02Dosage Protocols

Parameter

Mazdutide

Ovagen

Phase 2 studied dose

9 mg / weekJi 2026

Highest efficacy dose in obesity trial (BMI ≥30 kg/m²).Ji 2026

—

Frequency

Once weeklyJi 2026 Luo 2026

Once daily or cyclical (10–20 days per month)

Cyclical protocols common in Khavinson bioregulator tradition.

Route

SubcutaneousJi 2026

Oral (capsule) or subcutaneous

Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.

Dose escalation

3 mg → 6 mg → 9 mg (titration schedule in trials)

Gradual escalation to minimize GI side effects.

—

Evidence basis

Phase 2 RCT / Phase 3 ongoingJi 2026 Luo 2026

Theoretical / Russian-tradition

Duration (trials)

24–48 weeks

—

Population

Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities

—

Phase 3 comparator

Semaglutide 1 mg/week (DREAMS-3 trial)Luo 2026

—

Standard dose

—

10–20 mg / day (oral) or 1–2 mg SQ

Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.

Duration

—

4–12 weeks per cycle

Khavinson protocols typically 1–3 months; repeat cycles as needed.

03Metabolic / Fat Loss Evidence

Parameter

Mazdutide

Ovagen

Percentage body weight loss

12.4% (pooled meta-analysis, 9 mg dose)

95% CI: -16.15% to -8.68%, random-effects model.Azam 2026

—

Absolute weight loss

9.8 kg (mean)Azam 2026

95% CI: -13.15 to -6.37 kg.Azam 2026

—

Responder rate (≥10% loss)

Not explicitly reported in available abstracts

—

Mechanism

Appetite suppression (GLP-1) + energy expenditure (glucagon)Elmendorf 2026

—

BMI reduction

Significant reduction in Chinese adults BMI ≥30 kg/m²Ji 2026

—

Visceral fat

Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)

—

Glycemic improvement

HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)

—

Comparator efficacy

Head-to-head vs semaglutide 1 mg (Phase 3 pending publication)Luo 2026

—

Key publications

Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026

—

04Side Effects & Safety

Parameter

Mazdutide

Ovagen

Gastrointestinal symptoms

Nausea, vomiting, diarrhea (most common, GLP-1 effect)

—

Injection site reactions

Erythema, pruritus, local discomfort

—

Hypoglycemia

Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas

—

Cardiovascular effects

Increased heart rate (glucagon effect, transient)

—

Pancreatitis risk

Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain

—

Thyroid C-cell tumors

Black box warning for GLP-1 class (rodent data); human relevance unclear

—

Gallbladder disease

Cholelithiasis, cholecystitis (rapid weight loss effect)

—

Tolerability

Generally well-tolerated; GI effects diminish with dose titration

—

Reported adverse events

—

None documented in indexed literature

Theoretical hormonal effects

—

Ovarian stimulation — monitor for estrogen-sensitive conditions

Injection site reaction

—

Possible mild erythema (SQ route)

Long-term safety

—

Unknown — no PubMed-indexed RCTs

Absolute Contraindications

Mazdutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
·Hypersensitivity to mazdutide or excipients
·Pregnancy

Ovagen

·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
·Pregnancy

Relative Contraindications

Mazdutide

·History of pancreatitis
·Severe gastroparesis or GI motility disorders
·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
·Renal impairment (limited data, use with caution)

Ovagen

·History of estrogen-sensitive tumors (monitor)
·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
·Endometriosis or fibroids (estrogen-responsive conditions)

05Administration Protocol

Parameter

Mazdutide

Ovagen

1. Preparation

Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.

Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.

2. Injection site

Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.

1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.

3. Timing

Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.

Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.

4. Storage

Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.

5. Needle technique

Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.

—